What is the Purpose of this Study?
Primary Objective: To characterize safety and efficacy of 2 dose levels of AMG 193 by investigator.
Eligibility
- * Histologically or cytologically confirmed metastatic or unresectable locally advanced MTAP-deleted (Homozygous deletion of MTAP in the tumor tissue) non-small cell lung cancer
- * Participants will have received and progressed or experienced disease recurrence on or after receiving at least 1 prior systemic therapy for locally advanced and unresectable or metastatic disease.
- * Either an archival tissue sample or an archival block must be available.
- * Life expectancy of greater than 3 months, in the opinion of the investigator.
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center : Garrett Crook
More about this Clinical Trial
What is the full name of this clinical trial?
20230153: A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase -deleted Previously Treated Advanced Non-Small Cell Lung Cancer